WE’RE ALL IN
With our products, our people, and our infrastructure, Akston is 100% committed to pet-focused biotechnology.
Our mission:
The Biotech Pets Deserve
Akston exists to give pets the biotech they deserve in the form of therapies their families can afford. Pet health shouldn’t lag decades behind human health. At Akston, we’re bringing pets up to speed: With two classes of protein therapies designed specifically for pets, we’re imagining a world where pet therapies are developed independent of human biotech. Because better treatments make for better bonds with the pets we love.
COMPANY HISTORY
2024
Veterinary Insulin Programs
Sold to Dechra Limited
2023
KC Innovation Award
2023 recipient at Kansas City Animal Health SummitPivot to Animal Health
Vakston, Inc. Formed
Subsidiary of Akston for human vaccine candidatesDiamune Therapeutics, Inc. Formed
Subsidiary of Akston for human diabetes candidates
2022
First AKS-440 Patent Granted
Phase II Clinical Trials for Booster
AKS-452 in NetherlandsFirst AKS-452 Patent Granted
Phase II/III Clinical Trials
AKS-452 in India
2021
Phase II Clinical Trials
AKS-452 in NetherlandsPhase I/II Clinical Trials
AKS-452 in NetherlandsSecond Licensing Agreement of Veterinary Biologic Candidates
2020
Biologics Manufacturing Facility Commissioned
Phase I Clinical Trials
AKS-452 in NetherlandsFirst AKS-107 Patent Granted
Second Veterinary Insulin Patent Granted
First Veterinary Insulin Patent Granted
2019
First Licensing Agreement of Veterinary Biologic Candidates
Begin Building the Biologics Manufacturing Facility
2018
Awarded NIH/NIDDK Grant
Supporting Type 1 Diabetes Research
2017
Vet Candidates Developed
Canine Insulin and Feline Insulin CandidatesPartnership with Helmsley Charitable Trust
For Type 1 Diabetes Research
2015
First Ambifect® Platform Candidate
Type 1 Diabetes InterventionNew Research Lab Built
2012
Move to Cummings Center
Beverly, Massachusetts
2011
Akston Biosciences Corporation Incorporated
Akston founded by the team from SmartCells, Inc.
2010
Sale of SmartCells, Inc.
Sold to Merck & Co. in one of the largest preclinicalpharmaceutical acquisitions in history
Our Team
Todd Zion, Ph.D.
President and CEO
Thomas Lancaster, Ph.D.
Vice President, Manufacturing and Product Research and Development
Thillainaygam Sathiyaseelan, Ph.D.
Vice President, Quality and Regulatory Affairs
James Herriman
Vice President, Operations and CFO
Sylaja Murikipudi, Ph.D.
Senior Director of Quality Control
Manuel Valerio
Senior Director of Manufacturing Operations
Lauren Martin
Director of Human Resources
Board of Directors
Todd Zion, Ph.D.
Chairman of the Board
Ed Cannon, Ph.D.
Director
Robyn Davis
Director
Thomas Lancaster, Ph.D.
Director
Linda Rhodes, VMD, Ph.D.
Director
Rahul Bhansali
Director
Advisors
Gary P. Magnant
Technology Strategy
Horace Nalle
Of Counsel
Contact Akston
AKSTON BIOSCIENCES CORPORATION
100 Cummings Center, Suite 455B
Beverly, MA 01915
__name__
__title__
__bio__